CANC
Oncology ETF

Investing behind the prevention and cure of cancer

Why CANC ETF?

icons-themes-oncology-impact
Impact

Investors can provide capital to companies pioneering cures and early detection of cancer

icons-themes-oncology-innovation
Innovation

The life sciences industry is still in the early stages of a revolution in oncology innovations - from CAR-T cell therapies to bi-specific antibodies - powered by biological insights and growing capabilities

icons-themes-oncology-platforms
Research Expertise

The fund conducts deep and comprehensive research, in an effort to identify those companies that deliver breakthrough solutions at attractive valuations

icons-themes-oncology-growth
Growth

Oncology is an increasingly prioritized therapeutic class with treatment spend expected to grow substantially, driven by an aging population; this secular growth trend also tends to be insulated from economic cycles

icons-themes-oncology-uncorrelated
Uncorrelated

Performance of many biotechnology companies relies on clinical success which is an uncorrelated source of return

Fund Overview

Fund Details

As of December 06, 2024
Primary Exchange
Nasdaq
Ticker
CANC
AuM (USD)
$48,568,123
# of Holdings
50
Fund Inception Date
08/14/23
Gross Expense Ratio
0.99%
Net Expense Ratio*
0.75%
Implied Liquidity (# of shares)
ETF Implied liquidity is a representation of how many shares can potentially be traded daily in an ETF as portrayed by the creation unit. This is defined as the smallest value of the IDTS (Implied Daily Tradable Shares) for each holding in the creation unit.
1,075,311
Implied Liquidity (USD)
ETF Implied liquidity is a representation of how many shares can potentially be traded daily in an ETF as portrayed by the creation unit. This is defined as the smallest value of the IDTS (Implied Daily Tradable Shares) for each holding in the creation unit.
$30M
Shares Outstanding
1,760,000
Investment Advisor
Tema Global Limited
Sub-Investment Advisor
NEOS Investments, LLC
*Contractual expense cap for net expense ratio of 0.75% is in effect through 06/28/2027

Fund Summary

The actively managed Tema Oncology ETF seeks to provide long-term growth by investing in companies operating in the oncology industry. Cancer is the second deadliest killer but is on the brink of a revolution in therapeutics and diagnosis. Genetic sequencing and other forces are leading to a productivity surge, with oncology leading the way in new drug approvals. The growing complexity of scientific discovery, regulation and a surge in investment opportunities requires expertise to navigate this exciting chapter in human development.

Portfolio Manager

David K. Song, MD, PhD, CFA
Investment Partner
David K. Song, MD, PhD, CFA
David Song, Investment Partner, has led biotechnology and healthcare investment teams throughout his extensive 25-year career at Rockefeller Capital Management, Millennium and Balyasny. He studied Economics and Biochemistry at Yale, is a medical doctor and has a PhD in Applied Economics from Wharton.

How does the Tema CANC ETF fit in a portfolio?

Investment Style Box

Frame 48095809

Source: Tema. The investment style Box reveal’s a fund’s investment strategy by showing its investment style and market capitalization based on the fund’s portfolio holdings.

Potential Portfolio

Equity Allocation

3-5%

Equity Satellite

portfolio chart-Jan-12-2024-05-49-21-8745-PM
Ellipse 625

CANC ETF

Ellipse 625

Equity core

Where could a position be funded from?

  • Could be a more targeted alternative to existing healthcare or biopharma exposure in a portfolio.

  • Provides a balanced exposure across key oncology areas and company risk profiles.

  • Could replace a satellite or a growth-oriented position.

Portfolio Breakdown

Top 10 holdings

As of December 06, 2024
Company
% of Nav
REGENERON PHARMACEUTICALS, INC.
5.63%
GILEAD SCIENCES, INC.
5.43%
ASTRAZENECA PLC
5.27%
ARGENX SE
4.34%
BLUEPRINT MEDICINES CORP.
4.34%
INCYTE CORP.
4.33%
REVOLUTION MEDICINES, INC.
4.11%
ILLUMINA, INC.
3.78%
CHUGAI PHARMACEUTICAL CO., LTD.
3.43%
EXELIXIS, INC.
3.31%

Country Breakdown

United States
66.57%
United Kingdom
9.14%
Japan
6.51%
Netherlands
5.56%
Others
12.22%

Industry Breakdown

Healthcare
99.12%
Cash & Cash Equivalents
0.90%
  • Performance
  • Distributions
  • Premium / Discount

Prices & Performance

As of
Nov 30, 2024

CANC

3 months

1 Year

3 Years

5 Years

Since inception

NAV
-6.83% 5.29%
16.64% 23.04%
8.57% 11.85%
Market Price
-6.86% 5.30%
16.46% 23.33%
8.69% 12.10%

Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Returns for periods of less than one year are not annualized.


The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.

Distributions

Record Date

Ex-Date

Payable Date

Total Distribution

Income

ST Cap Gains

Dec 14, 2023
Dec 13, 2023
Dec 15, 2023
$0.149112
$0.134232
$0.014880
0.27 0.02 0.16 0.08 0.21 0.17 0.08 0.16 0.3 0.24 0.23 0.07 0.22 0.27 -0.07 0.1 0.05 0.11 0.26 -0.05 0.12

Premium/Discount

Сhart Table

CANC NAV / Market Price

NAV$27.60
NAV change (1D)$0.32
Median Bid/Ask Spread (30 Day)0.32%
Market Price$27.67
Market Price Change (1D)$0.39
Premium/Discount0.27%
As of: December 06, 2024

FAQ

What companies are included in Tema's Oncology ETF?

arrow

How many holdings are in the Tema Oncology ETF?

arrow

What is an oncology ETF?

arrow

How do oncology ETFs work?

arrow

How big is the oncology market?

arrow

Is cancer etf a good investment?

arrow

What are the benefits of investing in an oncology ETF?

arrow

What factors should I consider before investing in an oncology ETF?

arrow

Are oncology ETFs focused on specific types of cancer treatments?

arrow

How does an ETF focused on oncology differ from a general healthcare ETF?

arrow

What are the risks associated with investing in an emerging cancer ETF?

arrow

Can I invest in cancer research through cancer ETFs?

arrow

What role does biotechnology play in cancer ETFs?

arrow

How to buy

*Neither Tema Global Limited nor undefined ETF are affiliated with these financial services firms. Their listing should not be viewed as a recommendation or endorsement.